Search research articles
Contact Us
Filters
Showing results (101-110 of 127) with videos related to
Page
of 13
Sort By:
British Journal of Haematology
|
July 23, 1998
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients
P Moreau, V Leblond, P Bourquelot, et al.
Blood
|
March 10, 2001
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
T Facon, H Avet-Loiseau, G Guillerm, et al.
Bone Marrow Transplantation
|
November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)
M Mohty, M Attal, G Marit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E Terpos, O Sezer, P I Croucher, et al.
Blood
|
August 10, 1999
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial
T Facon, J L Harousseau, F Maloisel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 7, 2021
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>
M A Dimopoulos, P Moreau, E Terpos, et al.
Journal of Medical Economics
|
October 31, 2015
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma
S Z Usmani, J D Cavenagh, A R Belch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 127) with videos related to
Sort By:
Page
of 13
British Journal of Haematology
|
July 23, 1998
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients
P Moreau, V Leblond, P Bourquelot, et al.
Blood
|
March 10, 2001
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
T Facon, H Avet-Loiseau, G Guillerm, et al.
Bone Marrow Transplantation
|
November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)
M Mohty, M Attal, G Marit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E Terpos, O Sezer, P I Croucher, et al.
Blood
|
August 10, 1999
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial
T Facon, J L Harousseau, F Maloisel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 7, 2021
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>
M A Dimopoulos, P Moreau, E Terpos, et al.
Journal of Medical Economics
|
October 31, 2015
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma
S Z Usmani, J D Cavenagh, A R Belch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld, et al.
Page
of 13